Search hospitals > Pennsylvania > Scranton
Community Medical Center
Claim this profileScranton, Pennsylvania 18510
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Colorectal Cancer
Conducts research for Adenocarcinoma
104 reported clinical trials
15 medical researchers
Summary
Community Medical Center is a medical facility located in Scranton, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Community Medical Center is involved with conducting 104 clinical trials across 200 conditions. There are 15 research doctors associated with this hospital, such as Raghava Reddy Levaka Veera, Joseph J. Vadakara, Sorab Gupta, and Namita Sharma.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Raghava Reddy Levaka VeeraGeisinger Wyoming Valley/Henry Cancer Center4 years of reported clinical research
Expert in Cancer
Studies Adenocarcinoma
19 reported clinical trials
43 drugs studied
Joseph J. VadakaraGeisinger Medical Center5 years of reported clinical research
Studies Leukemia
Studies Lymphoma
20 reported clinical trials
60 drugs studied
Sorab GuptaGeisinger Medical Center3 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
13 reported clinical trials
24 drugs studied
Namita SharmaGeisinger Wyoming Valley/Henry Cancer Center4 years of reported clinical research
Studies Cancer
Studies Breast Cancer
11 reported clinical trials
29 drugs studied
Clinical Trials running at Community Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Multiple Myeloma
Melanoma
Cutaneous Melanoma
Ovarian Cancer
Fallopian Tube Cancer
Anal Squamous Cell Carcinoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Community Medical Center?
Community Medical Center is a medical facility located in Scranton, Pennsylvania. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Adenocarcinoma and other specialties. Community Medical Center is involved with conducting 104 clinical trials across 200 conditions. There are 15 research doctors associated with this hospital, such as Raghava Reddy Levaka Veera, Joseph J. Vadakara, Sorab Gupta, and Namita Sharma.